ABBV
AbbVie Inc.
NYSE · Healthcare · Drug Manufacturers - General · US
$256.34
−1.49%Jul 29, 2026, 07:00 UTC
The European Commission approved AbbVie's RINVOQ (upadacitinib) for treating adults and adolescents with non-segmental vitiligo.
Source:Jul 27, 2026, 13:19 UTC
Sarepta Therapeutics appointed Michael Severino as its new CEO, effective July 28, succeeding Doug Ingram who is retiring.
Source:Jul 17, 2026, 12:00 UTC
The European Commission approved Allergan Aesthetics' Boey (trenibotulinumtoxinE) for use in Europe for temporary improvement of glabellar lines in adult patients.
Source:Jul 14, 2026, 12:05 UTC
SkinMedica launched a Regenerative Science Advisory Board and expanded its R&D facility and retail experiences.
Source:Jul 10, 2026, 16:15 UTC
The U.S. House Select Committee on the Chinese Communist Party launched a bipartisan investigation into five major American pharmaceutical companies over clinical trials conducted in China, including at hospitals linked to the People's Liberation Army and in Xinjiang province, sending letters demanding records by July 17.
Jul 6, 2026, 17:45 UTC
The European Commission granted marketing authorization for AbbVie's TEPKINLY in combination with lenalidomide and rituximab for the treatment of relapsed or refractory follicular lymphoma.
Jul 3, 2026, 03:46 UTC
The U.S. House Select Committee on China sent an investigation letter to AbbVie, requesting explanations by July 17 regarding safety, IP protection, and ethical oversight of its clinical trials in China, including 17 in Xinjiang and 16 at military-affiliated institutions.
Source:Jul 3, 2026, 03:46 UTC
The U.S. FDA approved AbbVie's Skyrizi for treating pediatric plaque psoriasis and psoriatic arthritis, making it the first drug in its class approved for children under a certain weight.
Source:Jul 2, 2026, 11:55 UTC
Dingjin Biotech received FDA approval to use overseas (Taiwan) clinical data for a Phase 2 trial of OBI-858 in the US, targeting glabellar lines.
Source:Jun 30, 2026, 09:35 UTC
Genmab and AbbVie announced that their drug combination for lymphoma met the primary goal in a late-stage clinical trial.
Source:Jun 29, 2026, 20:15 UTC
AbbVie announced positive Phase 3 results for epcoritamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma.
Source:Jun 29, 2026, 07:00 UTC
AbbVie received a positive CHMP opinion recommending approval of upadacitinib (RINVOQ) for non-segmental vitiligo in adults and adolescents.
Jun 26, 2026, 20:50 UTC
The U.S. FDA approved AbbVie's SKYRIZI (risankizumab-rzaa) for pediatric use in psoriatic disease.
Source:Jun 24, 2026, 14:36 UTC
AbbVie received European Union approval for Skyrizi to treat pediatric plaque psoriasis, including a new weight-based dosing option.
Source:Jun 23, 2026, 12:00 UTC
Allergan Aesthetics received Health Canada approval for Boey (trenibotulinumtoxinE) for temporary improvement of glabellar lines in adults.
Source:Jun 23, 2026, 09:10 UTC
AbbVie received European Commission approval of MAVIRET (glecaprevir/pibrentasvir) for treating acute hepatitis C virus in the European Union.
Source:Jun 23, 2026, 07:00 UTC
The European Commission approved SKYRIZI (risankizumab) for pediatric patients with moderate to severe plaque psoriasis.
Source:Jun 19, 2026, 13:51 UTC
AbbVie reported promising results from the Phase 3 CLL14 trial for chronic lymphocytic leukemia.
Source:Jun 19, 2026, 13:51 UTC
AbbVie received FDA approvals for Decnupaz and Skinvive by Juvederm.
Source:Jun 18, 2026, 20:06 UTC
AbbVie Inc. declared a quarterly cash dividend of $1.73 per share, payable on August 14, 2026, to stockholders of record on July 15, 2026.
Source:Jun 16, 2026, 12:00 UTC
Allergan Aesthetics received U.S. FDA approval for SKINVIVE by JUVÉDERM to improve neck appearance in adults over 21.
Source:Jun 3, 2026, 23:04 UTC
The UK cost-effectiveness watchdog recommended AbbVie's ovarian cancer therapy Elahere for patients with a hard-to-treat form of ovarian cancer.
Source:Jun 3, 2026, 15:06 UTC
AbbVie received European Union approval for Aquipta as an acute treatment for migraine in adults.
Source:Jun 2, 2026, 08:00 UTC
The European Commission approved AbbVie's AQUIPTA (atogepant) for acute treatment and prophylaxis of migraine in adults in the European Union.
Source:
← PreviousPage 2